Annual Cash & Cash Equivalents
$32.40 M
+$19.81 M+157.34%
31 December 2023
Summary:
Trevi Therapeutics annual cash & cash equivalents is currently $32.40 million, with the most recent change of +$19.81 million (+157.34%) on 31 December 2023. During the last 3 years, it has fallen by -$4.43 million (-12.04%). TRVI annual cash & cash equivalents is now -43.47% below its all-time high of $57.31 million, reached on 31 December 2019.TRVI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$16.05 M
+$3.09 M+23.83%
30 September 2024
Summary:
Trevi Therapeutics quarterly cash and cash equivalents is currently $16.05 million, with the most recent change of +$3.09 million (+23.83%) on 30 September 2024. Over the past year, it has dropped by -$16.34 million (-50.45%). TRVI quarterly cash and cash equivalents is now -77.51% below its all-time high of $71.39 million, reached on 30 June 2019.TRVI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TRVI Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -50.5% |
| 3 y3 years | -12.0% | -56.4% |
| 5 y5 years | -43.5% | -72.0% |
TRVI Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -12.0% | +157.3% | -75.9% | +37.8% |
| 5 y | 5 years | -43.5% | +157.3% | -75.9% | +37.8% |
| alltime | all time | -43.5% | +349.8% | -77.5% | +122.9% |
Trevi Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $16.05 M(+23.8%) |
| June 2024 | - | $12.96 M(-6.1%) |
| Mar 2024 | - | $13.81 M(-57.4%) |
| Dec 2023 | $32.40 M(+157.3%) | $32.40 M(+24.8%) |
| Sept 2023 | - | $25.96 M(+88.8%) |
| June 2023 | - | $13.75 M(+18.0%) |
| Mar 2023 | - | $11.65 M(-7.5%) |
| Dec 2022 | $12.59 M(-65.8%) | $12.59 M(-81.1%) |
| Sept 2022 | - | $66.57 M(+169.6%) |
| June 2022 | - | $24.70 M(-15.2%) |
| Mar 2022 | - | $29.11 M(-21.0%) |
| Dec 2021 | $36.83 M | $36.83 M(+25.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $29.32 M(-19.5%) |
| June 2021 | - | $36.42 M(-12.4%) |
| Mar 2021 | - | $41.57 M(-7.6%) |
| Dec 2020 | $45.00 M(-21.5%) | $45.00 M(-15.6%) |
| Sept 2020 | - | $53.29 M(+20.6%) |
| June 2020 | - | $44.18 M(-16.1%) |
| Mar 2020 | - | $52.64 M(-8.2%) |
| Dec 2019 | $57.31 M(+695.8%) | $57.31 M(-9.8%) |
| Sept 2019 | - | $63.52 M(-11.0%) |
| June 2019 | - | $71.39 M(+451.4%) |
| Mar 2019 | - | $12.95 M(+79.8%) |
| Dec 2018 | $7.20 M(-67.3%) | $7.20 M |
| Dec 2017 | $22.02 M | - |
FAQ
- What is Trevi Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Trevi Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TRVI is $32.40 M
What is the all time high annual cash & cash equivalents for Trevi Therapeutics?
Trevi Therapeutics all-time high annual cash & cash equivalents is $57.31 M
What is Trevi Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TRVI is $16.05 M
What is the all time high quarterly cash and cash equivalents for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly cash and cash equivalents is $71.39 M
What is Trevi Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TRVI quarterly cash and cash equivalents has changed by -$16.34 M (-50.45%)